ISLET HOLDINGS, INC.

Trading Symbol: ISHI

Company Information and Continuing Disclosure Statement

for

The Quarter Ending March 31, 2015

October 9, 2015

ISLET HOLDINGS, INC.

Information and Disclosure for the Quarter Ending March 31, 2015

FORWARD LOOKING STATEMENTS

This Quarterly Disclosure contains forward-looking statements. To the extent that any statements made in this report contain information that is not historical, these statements are essentially forward looking. Forward-looking statements can be identified by the use of words such as "expects", "plans", "may,", "anticipates", "believes", "should", "intends", "estimates", and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, marketability of our products; legal and regulatory risks associated with being a publicly listed company; our ability to raise additional capital to finance our activities; the effectiveness, profitability and; the future trading of our common stock; our ability to operate as a public company; our ability to protect any proprietary information we own or may develop; general economic and business conditions; the volatility of our operating results and financial condition; our ability to attract or retain qualified senior management personnel and research and development staff; expansion into new and changing field of CBD production and sales; and other risks detailed from time to time in our filings with the OTC Markets (the "OTC"), or otherwise.

Information regarding relevant markets and industry contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

1) Name of the issuer and its predecessors (if any) within the past five years

Islet Holdings, Inc. (4/2009 to current)
Biozhem Cosmeceuticals, Inc. (8/1998 to 4/2009)

2) Address of the issuer's principal executive offices

Company Headquarters

c/o Littman Law Office
7609 Ralston Road
Arvada, Colorado 80002

Phone: 303-587-1435
Email: Info@isletholdings.com
Website: www.isletholdings.com

IR Contact
N/A

3) Security Information

Trading Symbol: ISHI

Exact title and class of securities outstanding:		Common Stock
CUSIP:		6467L102
Par or Stated Value:		$.0001
Total shares authorized as of:	7/28/2015:	1,000,000,000 common 100,000,000 preferred
Total shares outstanding as of:	7/28/2015:	206,200,000 common 0 preferred

Transfer Agent

Quicksilver Stock Transfer
6623 Las Vegas Blvd. South
Suite 255
Las Vegas, Nevada 89119
Phone: 702-629-1883

Is the Transfer Agent registered under the Exchange Act?* Yes: **X** No: _

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security: None

Trading suspension orders issued by the SEC in the past 12 months: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

In May of 2014 the Company increased its authorized common stock to 1,000,000,000 shares and preferred stock to 100,000,000 shares; par value was changed to $.0001 on both classes of stock.

4) Issuance History

Date	Recipient	Purpose of Issuance	Number of Shares	Restricted or Free
5/2014	Wayne Mower	Management	250,000,000*	R

*194,808,300 shares of this were canceled effective November 15, 2014

Post 2014 Year-end:

1/2015	Apollon Formularies Inc.	Contract	14,850,000	R
	Last Call Ventures, inc.	Contract	14,850,000	R
	Sheftall Bluff Development	Consulting	20,000,000	R
4/2015	HC Markowitz	Consulting	6,000,000	R
	Beach Brothers of Florida	Financing	500,000	R

All certificates or other documents that evidence the shares contain a legend stating that the shares have not been registered under the Securities Act and setting forth or refer to the restrictions on transferability and sale of the shares under the Securities Act.

5) Financial Statements

The Company's unaudited financial statements for the quarter ending March 31, 2015 are posted to www.otcmarkets.com on or about October 9, 2015 and are incorporated herein by reference.

6) Describe the Issuer's Business, Products and Services

1999 to 2013

For the decade prior to 2009, the Company was engaged in the production, marketing, and sales of premium quality bioeneginered and botanically based-skin care products. In April 2009 the Company's shareholders authorized a name change from Biozhem Cosmeceuticals, Inc. to the current name and effectuated a 500 to 1 reverse stock split. Thereafter, the Company acquired Isletech, Inc., a Nevada corporation formed to acquire certain intellectual property in the medical

field of treating Type 1 diabetes. Thereafter, the Company modified its prior focus on cosmeceuticals and continued its operations, but as a biotech medical company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with conditions of insulin-dependent diabetes. This is the primary target group who is believed could benefit from cell-based replacement treatments. The Company reported these developments in a press release June 19, 2009.

Following disagreements in later 2009 and 2010 with certain parties related to the Company's work and development in the Type 1 diabetes treatment industry, the Company was forced to file suit to protect the patents and other intellectual property it acquired in 2009. In August 2012, the Company and its subsidiary filed suit in Federal District Court for the District of Utah. Despite intermittent settlement discussions, the matter remains unresolved and the Company continues to devote resources to protect its patents and other intellectual property.

2014 to Present

In the first quarter of 2014 the Company commenced research into developing markets in the cannabis industry. In particular, the Company became interested in the use of cannabinoids in general, and cannabidiol (CBD) in particular, for treatment of a variety of medical ailments. This interest was accentuated as Utah went through a very public debate regarding changing its laws in March 2014 to allow the use of CBD in cases of epilepsy. During that time, Utah Governor Gary Herbert stated "Cannabis oils show promise of offering some relief to Utahns suffering from seizures and epilepsy and we should do all we can to help them." Media reports of that same period stated that there were some 3,500 people on waiting lists for CBD oil.

Additionally, Colorado recently enacted new legislation allowing the cultivation and harvesting of "hemp" plants that conform to a general maximum of .3% tetrahydrocannabinol ("THC") content. THC is psychoactive element within the Cannabis plant that is desired by recreational users of marijuana. Hemp, which is a Cannabis plant, is generally bred to minimize, if not completely eliminate, THC from the plant. Consequently, such breading focuses hemp farming on products that a far distant from any psychoactive properties that might impact other public policy issues. The first "Colorado legal" hemp crops were harvested in the fall of 2014, which harvesting generally focused on the creation of seed supplies for 2015 and 2016 planting.

Following the third quarter of 2014, the Company actively commenced investigation and development of hemp growing operations within Colorado for the purpose of securing a reliable domestic source of hemp plant from which to extract CBDs. The Company is pursuing Colorado hemp sources, as well as other potential domestic hemp sources in States that legalize the farming of hemp.

Cannabidiol is one of over 85 different cannabinoids within the cannabis plant. Cannabinoids are a class of diverse chemical compounds that act on "cannabinoid receptors" of cells that repress neurotransmitter releases in the brain. These receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured chemically). Perhaps the most

famous cannabinoid is THC, the primary psychoactive compound of cannabis commonly known as marijuana. . A *US News and World Report* article from March 11, 2015 states:

> Marijuana is a Schedule I drug under the Controlled Substances Act, which means under federal law it has no accepted medical value. *CBD, however, does not produce a high and research into the compound is on the upswing as parents of epileptic children and others flee to states that allow its use.*

The medicinal and health value of CBD has been widely publicized in recent years as state legislatures have moved to legalize the sale of CBD to meet the growing recognition of its medicinal and health benefits for its citizens. Many companies claim to include CBD oil in their products, though news from the FDA in 2015 indicates that many of these products have much less CBD than advertised, and some contain none at all. In late February 2015, the FDA issued a news release regarding companies marketing products that purportedly contain CBD. In that release the FDA states: "Some of these firms claim that their products contain CBD. FDA has tested those products and, in some of them, *did not detect any* CBD."

In addition to the overstated CBD content labels, reports in the past twelve months have indicated that foreign sources of CBD sometimes contain contaminants which actually harm those who have ingested it for medical reasons. Thus, some CBD market participants not only fail conduct themselves ethically as to product labeling, they have also obtained CBD from sources that do not meet American pharmaceutical "best practice" guidelines.

As a continuation of its 2009 work in the biotechnology and medical technology sectors for treatment of Type 1 diabetes through islet transplantation, the Company is now engaged in expanded research, exploration, development and production of products involving the medical and health benefits of CBD. While the Company currently believes in the "holistic" benefits of the entire cannabis plant (people benefitting from the presence CBD with other cannabinoids), the Company currently intends to initially pursue CBD as a beneficial cannabinoid for the general public. Further expansion by the Company into other cannabis products would require additional changes in federal and state laws. Thus, it is the Company's current intent to become a leader in domestic CBD sourcing wherein the highest standards of product creation and handling are followed and verified by independent laboratories.

In January 2015, the Company entered into an agreement with Apollon Formularies, Inc. to 1) acquire CBD derived from hemp farming in Jamaica, 2) formulate CBD infused products for the company, and 3) sell CBD infused products in Jamaica. The Company believes that Apollon will successfully obtain a license for hemp production in Jamaica, though at the time of this report that had not yet occurred. The Company also entered into an agreement with Last Call Ventures, Inc., an affiliate of Apollon, to acquire products it has developed and benefit from its industry contacts and associations. During the quarter, the Company issued 49,700,000 shares for the Apollon and Last Call agreement and for consulting in conjunction with expansion into CBD research, development, and production (see Item 8C below). Additionally, at the time of this report, the Company had provided over $500,000 in funding to Apollon and Last Call. These funds, along with shares issued in connection with these agreements and endeavors, represent a major investment and

commitment on the part of the Company to obtain reliable sources of CBD and develop opportunities in nutraceutical products.

The Company has also entered into a "Sponsorship Agreement for the Research, Development and Trial Testing of New Agricultural Crops" with SproutHouse LLC in Colorado. The SproutHouse Agreement provides for the acquisition of CBD from Colorado hemp and data for the domestic growing of various strains of hemp and subsequent CBD extraction.

As an industry, domestic development of CBD and other products from hemp is in its infancy and remains a challenging endeavor that is fraught with regulatory and practical obstacles that do not exist in other well-established industries. The Company's diversification into development through opportunities is intended to minimize some obstacles. Nonetheless, international agreements and operations typically have their own paradigm of challenges.

The Company is endeavoring to utilize both domestic and international opportunities to develop as a reputable supplier of CBD for use in a wide variety of products, including rapidly emerging medicinal and general health applications.

A. Date and State of Incorporation: Nevada; December 10, 1981

B. Issuer's primary & secondary SIC Codes: 8731 and 87330103

C. The issuer's fiscal year end date: December 31

D. Principal products or services, and their markets: See above.

7) Describe the Issuer's Facilities

Though the Company is currently reviewing several locations with which to establish a processing plant in the extended Denver area, the Company currently has no material physical assets or facilities at August 1, 2015. The Company's primary current asset consists of all the intellectual property developed by former NASDAQ-listed biomedical company Microislet, Inc., which the Company acquired at a bankruptcy auction in 2009.

8) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

The sole officer and director is J. Michael Heil, who serves as Director, President, CEO, Sec/Tres.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses):

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities:

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated:

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities:

None

C. Beneficial Shareholders.

Name	Number of Shares	Percent as of 6/1/2015
J. Michael Heil (Dir/CEO, Pres)	108,000,000	52.4%
Sheftall Bluff Development Corp.	20,000,000	9.7%
Apollon Formularies, Inc.	14,850,000	7.1%
Last Call Ventures, Inc.	14,850,000	7.1%

9) Third Party Providers

Legal Counsel: Michael A. Littman, Attorney at Law, 7609 Ralston Road, Arvada, Colorado 80002; Phone: 303-422-8127; Email: malattyco@gmail.com

Accounting: Mainstreet Consulting and Accounting, Inc., 10 West Broadway, Suite 609, Salt Lake City, Utah 84101.

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, J. Michael Heil, certify that:

1. I have reviewed this Disclosure Statement of Islet Holdings, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

October 9, 2015

/s/ J. Michael Heil
President and CEO